Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.

Rhea-AI Summary

Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 9:50 a.m. ET.

A live webcast will be available via the company’s Investors "Events & Presentations" page and a replay will be archived for 30 days following the presentation.

Argus Feb 24 session

+1.43% close to close Open Argus

Details

News Market Reaction – ANNX

On Feb 24, the day this news came out, ANNX closed 1.43% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Market Context

This announcement highlights Annexon’s planned presentation at the TD Cowen 46th Annual Health Care ...

Analysis

This announcement highlights Annexon’s planned presentation at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, extending a pattern of active investor engagement. It follows recent updates on 2026 milestones, including European MAA progress and key Phase 3 timelines. Investors may focus on any incremental color about the neuroinflammatory franchise, including programs affecting nearly 10 million patients, and how management frames upcoming clinical and regulatory catalysts during the webcast.

Key Figures

Patient population impacted: 10 million people worldwide Conference date: March 3, 2026 Presentation time: 9:50 a.m. ET +1 more

Patient population impacted

10 million people worldwide

Neuroinflammatory diseases targeted by Annexon platform

Conference date

March 3, 2026

TD Cowen 46th Annual Health Care Conference presentation

Presentation time

9:50 a.m. ET

Scheduled time for TD Cowen conference presentation

Webcast replay period

30 days

Replay archived on Annexon website following presentation

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   KOL event announcement

   24h Move

   +3.1%

   Announced March KOL event and timeline for ARCHER II Phase 3 topline data.

2. Jan 16

   Inducement grants

   24h Move

   +1.5%

   Reported stock option inducement awards to new employees under Nasdaq rules.

3. Jan 12

   Pipeline priorities

   24h Move

   +5.9%

   Outlined 2026 platform milestones, including MAA filing and key trial readouts.

4. Jan 8

   EMA MAA submission

   24h Move

   -4.3%

   Submitted MAA to EMA for tanruprubart in Guillain-Barré syndrome.

5. Jan 7

   JPM conference presentation

   24h Move

   +8.4%

   Announced upcoming presentation at the J.P. Morgan Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuroinflammatory, immunotherapies, webcast

3 terms

neuroinflammatory medical

"immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people"

Neuroinflammatory describes inflammation occurring in the brain, spinal cord or peripheral nerves when the body's immune response becomes active in nervous tissue. For investors, it matters because neuroinflammatory processes are central to many neurological diseases and can drive demand for new drugs, affect clinical trial outcomes, and influence regulatory decisions—similar to how a neighborhood dispute can change local services and property values, inflammation can reshape treatment needs and company prospects.

immunotherapies medical

"advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

webcast technical

"A live webcast of the event can be accessed under the ‘Events & Presentations’ section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Annexon (ANNX) present at the TD Cowen 46th Annual Health Care Conference?

Annexon (ANNX) will present on March 3, 2026 at 9:50 a.m. ET. According to Annexon, Douglas Love, president and CEO, will deliver the presentation and address company strategy and recent developments to conference attendees and investors.

How can investors watch the Annexon (ANNX) presentation on March 3, 2026?

Investors can watch a live webcast through Annexon’s Investors "Events & Presentations" page. According to Annexon, the webcast will stream live and a replay will be archived on the company website for 30 days after the event.

Who is presenting for Annexon (ANNX) at the TD Cowen conference on March 3, 2026?

Douglas Love, president and chief executive officer, will present for Annexon (ANNX). According to Annexon, he will outline corporate priorities and provide updates during his scheduled 9:50 a.m. ET slot on March 3, 2026.

Will a replay of the Annexon (ANNX) March 3, 2026 presentation be available after the conference?

Yes, a replay will be available and archived for 30 days on the company website. According to Annexon, the archived webcast can be accessed via the Investors "Events & Presentations" page following the live event.